Immunitybio Pretax Profit Margin from 2010 to 2024

IBRX Stock  USD 4.91  0.33  6.30%   
Immunitybio Pretax Profit Margin yearly trend continues to be fairly stable with very little volatility. Pretax Profit Margin will likely drop to -985.67 in 2024. During the period from 2010 to 2024, Immunitybio Pretax Profit Margin regression line of annual values had significance of  0.19 and arithmetic mean of (833.86). View All Fundamentals
 
Pretax Profit Margin  
First Reported
2010-12-31
Previous Quarter
(938.73)
Current Value
(985.67)
Quarterly Volatility
934.49092979
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Immunitybio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunitybio main balance sheet or income statement drivers, such as Depreciation And Amortization of 11.2 M, Interest Expense of 135.7 M or Selling General Administrative of 91.7 M, as well as many exotic indicators such as Price To Sales Ratio of 3.9 K, Dividend Yield of 3.0E-4 or Days Sales Outstanding of 1.8 K. Immunitybio financial statements analysis is a perfect complement when working with Immunitybio Valuation or Volatility modules.
  
This module can also supplement Immunitybio's financial leverage analysis and stock options assessment as well as various Immunitybio Technical models . Check out the analysis of Immunitybio Correlation against competitors.
For more information on how to buy Immunitybio Stock please use our How to Invest in Immunitybio guide.

Latest Immunitybio's Pretax Profit Margin Growth Pattern

Below is the plot of the Pretax Profit Margin of Immunitybio over the last few years. It is Immunitybio's Pretax Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunitybio's overall financial position and show how it may be relating to other accounts over time.
Pretax Profit Margin10 Years Trend
Slightly volatile
   Pretax Profit Margin   
       Timeline  

Immunitybio Pretax Profit Margin Regression Statistics

Arithmetic Mean(833.86)
Coefficient Of Variation(112.07)
Mean Deviation773.53
Median(374.56)
Standard Deviation934.49
Sample Variance873,273
Range2.7K
R-Value(0.36)
Mean Square Error818,863
R-Squared0.13
Significance0.19
Slope(75.13)
Total Sum of Squares12.2M

Immunitybio Pretax Profit Margin History

2024 -985.67
2023 -938.73
2022 -1738.69
2021 -374.56
2020 -373.61
2019 -72.78
2018 -2058.06

About Immunitybio Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Immunitybio income statement, its balance sheet, and the statement of cash flows. Immunitybio investors use historical funamental indicators, such as Immunitybio's Pretax Profit Margin, to determine how well the company is positioned to perform in the future. Although Immunitybio investors may use each financial statement separately, they are all related. The changes in Immunitybio's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Immunitybio's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Immunitybio Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Immunitybio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Pretax Profit Margin(938.73)(985.67)

Immunitybio Investors Sentiment

The influence of Immunitybio's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Immunitybio. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Immunitybio's public news can be used to forecast risks associated with an investment in Immunitybio. The trend in average sentiment can be used to explain how an investor holding Immunitybio can time the market purely based on public headlines and social activities around Immunitybio. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Immunitybio's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Immunitybio's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Immunitybio's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Immunitybio.

Immunitybio Implied Volatility

    
  412.13  
Immunitybio's implied volatility exposes the market's sentiment of Immunitybio stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Immunitybio's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Immunitybio stock will not fluctuate a lot when Immunitybio's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Immunitybio in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Immunitybio's short interest history, or implied volatility extrapolated from Immunitybio options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Immunitybio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Immunitybio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immunitybio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immunitybio Stock:
Check out the analysis of Immunitybio Correlation against competitors.
For more information on how to buy Immunitybio Stock please use our How to Invest in Immunitybio guide.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Complementary Tools for Immunitybio Stock analysis

When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Fundamental Analysis
View fundamental data based on most recent published financial statements
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Is Immunitybio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunitybio. If investors know Immunitybio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunitybio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.15)
Revenue Per Share
0.001
Quarterly Revenue Growth
0.904
Return On Assets
(0.52)
The market value of Immunitybio is measured differently than its book value, which is the value of Immunitybio that is recorded on the company's balance sheet. Investors also form their own opinion of Immunitybio's value that differs from its market value or its book value, called intrinsic value, which is Immunitybio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunitybio's market value can be influenced by many factors that don't directly affect Immunitybio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunitybio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunitybio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunitybio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.